Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients

Abdullah S. Al Saleh, M. Hasib Sidiqi, Angela Dispenzieri, Prashant Kapoor, Eli Muchtar, Francis K. Buadi, Rahma Warsame, Martha Q. Lacy, David Dingli, Nelson Leung, Wilson I. Gonsalves, Taxiarchis V. Kourelis, Morie A. Gertz, Ronald S. Go, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar

Research output: Contribution to journalArticle

Abstract

Risk stratification of multiple myeloma (MM) at diagnosis is critical. We examined the ability of hematopoietic indices including mean corpuscular volume (MCV), hemoglobin (Hgb), and platelet (Plt) to predict outcomes. This was a retrospective study of patients treated at Mayo Clinic between January 2004 and April 2018. We incorporated three variables (Hgb < 10 g/dL, Plt < 150 × 109/L, and MCV > 96 fL), assigning a score of 1 to each. We identified 1540 newly diagnosed MM patients, of whom 707 (46%) had a score of 0, 513 (33%) had a score of 1, 260 (17%) had a score of 2, and 60 (4%) had a score of 3. The score risk stratified patients into four groups with differing survivals. The median PFS was 32.3 months for score 0, 24.8 months for score 1, 21.7 months for score 2, and 18.3 months for score 3, for P <.001. The median OS was 80.7 months for score 0, 59.9 months for score 1, 51.7 months for score 2, and 31.3 months for score 3, P <.0001. Predictors of OS on the multivariable analysis were age ≥ 65 (HR, 1.93; P <.0001), R-ISS stage (1-2 vs 3) (HR, 0.48; P <.0001), and hematopoietic score (0-2 vs 3) (HR, 0.51; P =.006). A hematopoietic score can predict survival in newly diagnosed myeloma patients.

Original languageEnglish (US)
JournalAmerican journal of hematology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Multiple Myeloma
Erythrocyte Indices
Survival
Hemoglobins
Blood Platelets
Retrospective Studies

ASJC Scopus subject areas

  • Hematology

Cite this

Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. / Al Saleh, Abdullah S.; Sidiqi, M. Hasib; Dispenzieri, Angela; Kapoor, Prashant; Muchtar, Eli; Buadi, Francis K.; Warsame, Rahma; Lacy, Martha Q.; Dingli, David; Leung, Nelson; Gonsalves, Wilson I.; Kourelis, Taxiarchis V.; Gertz, Morie A.; Go, Ronald S.; Kyle, Robert A.; Rajkumar, S. Vincent; Kumar, Shaji K.

In: American journal of hematology, 01.01.2019.

Research output: Contribution to journalArticle

@article{9e25aa0ad59f4c058da4ca371de3e085,
title = "Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients",
abstract = "Risk stratification of multiple myeloma (MM) at diagnosis is critical. We examined the ability of hematopoietic indices including mean corpuscular volume (MCV), hemoglobin (Hgb), and platelet (Plt) to predict outcomes. This was a retrospective study of patients treated at Mayo Clinic between January 2004 and April 2018. We incorporated three variables (Hgb < 10 g/dL, Plt < 150 × 109/L, and MCV > 96 fL), assigning a score of 1 to each. We identified 1540 newly diagnosed MM patients, of whom 707 (46{\%}) had a score of 0, 513 (33{\%}) had a score of 1, 260 (17{\%}) had a score of 2, and 60 (4{\%}) had a score of 3. The score risk stratified patients into four groups with differing survivals. The median PFS was 32.3 months for score 0, 24.8 months for score 1, 21.7 months for score 2, and 18.3 months for score 3, for P <.001. The median OS was 80.7 months for score 0, 59.9 months for score 1, 51.7 months for score 2, and 31.3 months for score 3, P <.0001. Predictors of OS on the multivariable analysis were age ≥ 65 (HR, 1.93; P <.0001), R-ISS stage (1-2 vs 3) (HR, 0.48; P <.0001), and hematopoietic score (0-2 vs 3) (HR, 0.51; P =.006). A hematopoietic score can predict survival in newly diagnosed myeloma patients.",
author = "{Al Saleh}, {Abdullah S.} and Sidiqi, {M. Hasib} and Angela Dispenzieri and Prashant Kapoor and Eli Muchtar and Buadi, {Francis K.} and Rahma Warsame and Lacy, {Martha Q.} and David Dingli and Nelson Leung and Gonsalves, {Wilson I.} and Kourelis, {Taxiarchis V.} and Gertz, {Morie A.} and Go, {Ronald S.} and Kyle, {Robert A.} and Rajkumar, {S. Vincent} and Kumar, {Shaji K.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/ajh.25657",
language = "English (US)",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients

AU - Al Saleh, Abdullah S.

AU - Sidiqi, M. Hasib

AU - Dispenzieri, Angela

AU - Kapoor, Prashant

AU - Muchtar, Eli

AU - Buadi, Francis K.

AU - Warsame, Rahma

AU - Lacy, Martha Q.

AU - Dingli, David

AU - Leung, Nelson

AU - Gonsalves, Wilson I.

AU - Kourelis, Taxiarchis V.

AU - Gertz, Morie A.

AU - Go, Ronald S.

AU - Kyle, Robert A.

AU - Rajkumar, S. Vincent

AU - Kumar, Shaji K.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Risk stratification of multiple myeloma (MM) at diagnosis is critical. We examined the ability of hematopoietic indices including mean corpuscular volume (MCV), hemoglobin (Hgb), and platelet (Plt) to predict outcomes. This was a retrospective study of patients treated at Mayo Clinic between January 2004 and April 2018. We incorporated three variables (Hgb < 10 g/dL, Plt < 150 × 109/L, and MCV > 96 fL), assigning a score of 1 to each. We identified 1540 newly diagnosed MM patients, of whom 707 (46%) had a score of 0, 513 (33%) had a score of 1, 260 (17%) had a score of 2, and 60 (4%) had a score of 3. The score risk stratified patients into four groups with differing survivals. The median PFS was 32.3 months for score 0, 24.8 months for score 1, 21.7 months for score 2, and 18.3 months for score 3, for P <.001. The median OS was 80.7 months for score 0, 59.9 months for score 1, 51.7 months for score 2, and 31.3 months for score 3, P <.0001. Predictors of OS on the multivariable analysis were age ≥ 65 (HR, 1.93; P <.0001), R-ISS stage (1-2 vs 3) (HR, 0.48; P <.0001), and hematopoietic score (0-2 vs 3) (HR, 0.51; P =.006). A hematopoietic score can predict survival in newly diagnosed myeloma patients.

AB - Risk stratification of multiple myeloma (MM) at diagnosis is critical. We examined the ability of hematopoietic indices including mean corpuscular volume (MCV), hemoglobin (Hgb), and platelet (Plt) to predict outcomes. This was a retrospective study of patients treated at Mayo Clinic between January 2004 and April 2018. We incorporated three variables (Hgb < 10 g/dL, Plt < 150 × 109/L, and MCV > 96 fL), assigning a score of 1 to each. We identified 1540 newly diagnosed MM patients, of whom 707 (46%) had a score of 0, 513 (33%) had a score of 1, 260 (17%) had a score of 2, and 60 (4%) had a score of 3. The score risk stratified patients into four groups with differing survivals. The median PFS was 32.3 months for score 0, 24.8 months for score 1, 21.7 months for score 2, and 18.3 months for score 3, for P <.001. The median OS was 80.7 months for score 0, 59.9 months for score 1, 51.7 months for score 2, and 31.3 months for score 3, P <.0001. Predictors of OS on the multivariable analysis were age ≥ 65 (HR, 1.93; P <.0001), R-ISS stage (1-2 vs 3) (HR, 0.48; P <.0001), and hematopoietic score (0-2 vs 3) (HR, 0.51; P =.006). A hematopoietic score can predict survival in newly diagnosed myeloma patients.

UR - http://www.scopus.com/inward/record.url?scp=85074684165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074684165&partnerID=8YFLogxK

U2 - 10.1002/ajh.25657

DO - 10.1002/ajh.25657

M3 - Article

C2 - 31612526

AN - SCOPUS:85074684165

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

ER -